{"name":"Kling Biotherapeutics B.V.","slug":"kling-biotherapeutics-b-v","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQcmhkTlVZZ3pfOWhxa2E4X1UwOW9nc1JrYnlUTzBoZjhSRUdqUld2amVhVlU2X0Y0bkZZajBfQjU3Znc0SDBnaFVEaWc0OVRjcHRtM3BTaXhueTE4WWlyUENxU1pjUFhqd1pvYVNLS1lnbVJDMlhxN2U5TDhCRjBvRlpHblFlSUpKbU9fT29sTFJnLXJGeXlpLTF3NUdFdVdINktOcGRKVTItU01jeGVhd1puVnQ1Ukl0dlZIcWpaa2RBdw?oc=5","date":"2024-02-27","type":"pipeline","source":"BioWorld News","summary":"Kling Biotherapeutics’ KBA-1413 recognizes a specific form of CD43 useful for cancer - BioWorld News","headline":"Kling Biotherapeutics’ KBA-1413 recognizes a specific form of CD43 useful for cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxPQWpzUlkwbDg5TUlQRTZOTENIWGd1WWtDc3E5SWlkOVgtLVpqdzZEVWJoaU5LZjgzamgtbU5QRXdLSXlPYzNqbFRYbk9NR1hCbGtxaXVLdVA1eEtqMlJnZUphMXAzbHFlUllnR2tKUGp5Y1pDejhZSHdkaVU5V21NX25wTmNWa05teW14dWxIZGpVM3ZUMzVGZFlIVlpKdUVtSk05SEpwcUhtQWZDLWVxLXlnLUJfY1ZobXZrNWVYb3dpeG9jNDMxeFpweGNrd1NiLVFMVHVybWNwMnVkaUtlZFJuYXpiNC0xb2Jnb1BmUFNZRkhOQkwwTFd1dkRlU2RBaWY1Mm9iREJtZ3pSS0dYeVlB?oc=5","date":"2022-09-29","type":"trial","source":"PR Newswire","summary":"Kling Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical trial of KBA1412 in Patients with Advanced Solid Tumors - PR Newswire","headline":"Kling Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical trial of KBA1412 in Patients with Advanced Soli","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}